Last reviewed · How we verify

NCT06638814: HEAD-IBD-II

HEmorrhoidAl Disease in Inflammatory Bowel Disease: a Multicenter Prospective Cohort Study

Not yet recruiting Last updated 15 October 2024
What this trial tests

trial in IBD (Inflammatory Bowel Disease) in 50 participants. Not yet recruiting.

Timeline
1 January 2025
Primary endpoint
31 December 2026
31 January 2027

Quick facts

Lead sponsorTreviso Regional Hospital
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment50
Start date1 January 2025
Primary completion31 December 2026
Estimated completion31 January 2027

Conditions studied

Sponsor

Treviso Regional Hospital

Who can join

18 and older, any sex, with IBD (Inflammatory Bowel Disease) or Hemorrhoid. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients who will undergo surgery for HD after the diagnosis of IBD over a 12-month period will be enrolled across Europe. Primary objective of this study is to determine the safety and effectiveness of surgical treatments for HD in a large multicenter cohort of IBD patients. Secondary aim is to identify factors that may affect clinical and surgical outcomes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for IBD (Inflammatory Bowel Disease)

Currently open trials in the same condition.

Other Treviso Regional Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06638814.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing